Sign Up Today and Learn More About Gliknik Stock
Invest in or calculate the value of your shares in Gliknik or other pre-IPO companies through EquityZen's platform.
Gliknik Stock (GLIK)
Gliknik develops therapies for patients with cancer and immune disorders.
About Gliknik Stock
Founded
2007
Headquarters
Baltimore, MD, US
Total Funding
53.6M
Industries
Software, Artificial Intelligence, Data and Analytics
Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the efficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to monocolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.
Gliknik Press Mentions
Stay in the know about the latest news on Gliknik
Manufacturing optimization of gl-2045, a multimerizing stradomer
patents • Feb 11, 2025
Fusion proteins of human protein fragments to create orderly multimerized …
patents • Feb 11, 2025
Ace2-fc fusion proteins and methods of use
patents • Feb 11, 2025
Baltimore VC investments jump to $158M in 2024’s final quarter
technical • Feb 06, 2025
Baltimore's Q3 Venture Monitor report is out. An expert thinks ...
technical • Dec 23, 2023
Gliknik Management
Leadership team at Gliknik
Founder, President and CEO
David S. Block
Founder & Scientist
Scott E. Strome
Join now and verify your accreditation status to gain access to:
- Gliknik Current Valuation
- Gliknik Stock Price
- Gliknik Management
- Available deals in Gliknik and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Gliknik Cap Table and Funding History by Share Class and Liquidity Preferences
- Gliknik Revenue and Financials
- Gliknik Highlights
- Gliknik Business Model
- Gliknik Risk Factors
- Gliknik Research Report from SACRA Research
Trading Gliknik Stock
How to invest in Gliknik stock?
Accredited investors can buy pre-IPO stock in companies like Gliknik through EquityZen funds. These investments are made available by existing Gliknik shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Gliknik stock?
Shareholders can sell their Gliknik stock through EquityZen's private company marketplace. EquityZen's network includes over 350K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 44K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
